TP53 and neoplasm: A non-specific molecular profile (NSMP) and MMR-deficient/β-catenin mutation tumours are classified as intermediate risk and are allocated to the VBT arm, whereas mutated p53, substantial LVSI or >10% L1 cell adhesion molecule (L1CAM) expression of the tumours is classified as high risk and is allocated to the EBRT arm [42].